Medication Management for Aggression in Adolescents with Down Syndrome

Treatment Algorithm

The American Academy of Child and Adolescent Psychiatry recommends atypical antipsychotics, particularly risperidone, as the first-line pharmacological treatment for aggression in adolescents with Down syndrome, but only after behavioral interventions have been implemented and comorbid conditions have been addressed 1, 2, 3
Behavioral parent training and applied behavior analysis must be initiated before or alongside any medication, as these demonstrate large effect sizes and are the foundation of treatment 4
If ADHD is present, stimulants are first-line treatment, as they reduce both ADHD symptoms and aggressive behaviors 1, 5, 6
If mood dysregulation or bipolar disorder is suspected, mood stabilizers should be considered before antipsychotics 1, 6

Risperidone is the preferred agent, with the strongest evidence showing 69% response rate versus 12% on placebo for severe aggression in youth 6, 3, 4
Starting dose: 0.25 mg/day for children <20 kg or 0.5 mg/day for children ≥20 kg 3
Titration: Increase by 0.25-0.5 mg every 5-7 days (or every 2 weeks for more cautious approach) based on response and tolerability 3
Target therapeutic range: 1-2 mg/day for most adolescents, with mean effective doses of 1.16-1.9 mg/day in controlled trials 3
Maximum dose: 2.5 mg/day, as doses above this show no additional benefit but increased adverse effects 3
Aripiprazole is an alternative, FDA-approved for irritability in adolescents aged 13-17 years, with typical dosing of 5-10 mg/day 6, 3

Monitor weight, height, and BMI at baseline and each visit for the first 3 months, then monthly 3
Check metabolic parameters (fasting glucose, lipid panel) and prolactin levels periodically, as individuals with Down syndrome may be at higher risk for metabolic complications 6, 3
Monitor for extrapyramidal symptoms, dystonic reactions, and movement disorders 7, 3

Never use medication as the sole intervention—it must be combined with behavioral supports and parent training 1, 5, 3
Avoid polypharmacy: Trial one medication class thoroughly (6-8 weeks at therapeutic doses) before switching to another class rather than adding medications 1, 5, 6, 4
Establish a therapeutic alliance and obtain adolescent assent before prescribing, as prescribing only at parent request without the teen's support is unlikely to succeed 1, 5
Monitor adherence, compliance, and possible diversion carefully, especially with adolescents 1, 5
Obtain baseline behavioral data before starting medication to avoid attributing environmental improvements to the drug 1, 5

Avoid benzodiazepines for long-term use due to unfavorable risk-benefit profile and potential for paradoxical rage reactions 3, 4
Avoid antihistamines (hydroxyzine, diphenhydramine) for aggression, as they may cause paradoxical increase in rage 4
Chemical restraint (emergency IM medications) should only be used in inpatient psychiatric settings for acute crisis management, not as outpatient treatment 7, 4

Medication should facilitate the adolescent's ability to engage with educational and behavioral interventions, not replace them 3
Combining risperidone with parent training is moderately more efficacious than medication alone for decreasing serious behavioral disturbance 3, 4
Regular assessment using standardized rating scales (e.g., Aberrant Behavior Checklist) should guide dose adjustments 3